Loading clinical trials...
Loading clinical trials...
A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
Conditions
Interventions
trabectedin
pharmacological study
Locations
14
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Children's Hospital Central California
Madera, California, United States
Childrens Memorial Hospital
Chicago, Illinois, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
New York University Langone Medical Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Start Date
January 1, 2008
Primary Completion Date
October 1, 2010
Completion Date
December 1, 2013
Last Updated
September 14, 2018
NCT03155620
NCT01552434
NCT01614795
NCT01222715
NCT02509234
Lead Sponsor
Children's Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions